- The deal would expand Lunai’s capacity to develop treatments for neurological disorders.
- The transaction is executed through Series B Convertible Preferred shares at a fixed conversion price of $1.5 per share.
- The acquired technology enables compounds to remain inactive in the body until they reach the brain, where they are selectively activated.
Lunai Bioworks, Inc. (LNAI) announced a $20 million acquisition to advance its central nervous system (CNS) drug development.
The company will acquire blood-brain barrier (BBB) delivery technology and Alzheimer's therapeutic assets for $20 million from the Clemann Group, SAS, or its assignee, marking an expansion of Lunai’s capabilities in neurological drug research.
Transforming CNS Drug Delivery
The transaction is structured as Series B Convertible Preferred shares at a fixed conversion price of $1.5 per share, with a cap on beneficial ownership at 19.9% to remain compliant with Nasdaq regulations.
The newly acquired delivery platform addresses one of the most persistent challenges in central nervous system (CNS) drug development, which is the effective transport of therapeutics across the blood-brain barrier.
The technology ensures that compounds remain inactive in the body until reaching the brain, where they activate to target specific neurological pathways.
Lunai Bioworks stock traded over 25% higher on Thursday morning. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.
Strengthening Lunai’s Alzheimer’s Pipeline
This acquisition directly strengthens Lunai’s Alzheimer’s program by combining validated target identification with a strong delivery method. The platform enables advanced treatments for CNS disorders where conventional drugs face penetration limitations, potentially improving both safety and effectiveness.
"We are now combining the ability to identify the right biology with a validated mechanism to deliver therapies directly into the brain.”
— David Weinstein, CEO, Lunai Bioworks
On March 19, Lunai launched the Pathfinder Consortium, a national academic-industry alliance to accelerate the development of chemical countermeasures for battlefield and terrorism threats.
LNAI stock has declined by over 35% year-to-date.
Also See: Why Did AIFF Stock Surge Over 20% Pre-Market Today?
For updates and corrections, email newsroom[at]stocktwits[dot]com.